...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A,B amino acid triplet level on kidney transplant survival.
【24h】

HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A,B amino acid triplet level on kidney transplant survival.

机译:HLAmatchmaker:一种基于分子的组织相容性确定算法。三, HLA-A,B氨基酸三重态水平匹配对肾脏移植存活的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: HLAMatchmaker is a recently developed computer-based algorithm to determine donor-recipient HLA compatibility at the molecular level. Originally designed for highly alloimmunized patients, this algorithm is based on the concept that immunogenic epitopes are represented by amino acid triplets on exposed parts of protein sequences of HLA-A, -B, and -C chains accessible to alloantibodies. Donor HLA compatibility is determined by intralocus and interlocus comparisons of triplets in polymorphic sequence positions. For most patients, HLAMatchmaker can identify certain mismatched HLA antigens that are zero-triplet mismatches to the patient's HLA phenotype and should, therefore, be considered fully histocompatible. The present study was designed to determine how class I HLA matching at the triplet level affects kidney transplant outcome. METHODS: We analyzed two multicenter databases of zero-HLA-DR-mismatched kidneys transplanted from 1987 to 1999. One database consisted of 31,879 primary allografts registered by U.S. transplant centers in the United Network for Organ Sharing database and the other consisted of 15,872 transplants in the Eurotransplant program. RESULTS: HLA-A,B mismatched kidneys that were compatible at the triplet level exhibited almost identical graft survival rates as the zero-HLA-A,B antigen mismatches defined by conventional criteria. This beneficial effect of triplet matching was seen for both nonsensitized and sensitized patients and also for white and nonwhite patients. CONCLUSIONS: These findings suggest that the application of HLAMatchmaker will increase the number of successful transplants, at least in the HLA-DR match combinations.
机译:背景:HLAMatchmaker是最近开发的基于计算机的算法,用于在分子水平上确定供体-受体HLA的相容性。此算法最初是为高度同种异体免疫的患者设计的,基于以下概念:免疫原性表位由同种抗体可访问的HLA-A,-B和-C链蛋白序列的暴露部分上的氨基酸三联体表示。供体的HLA相容性由三态性在多态序列位置的基因座内和基因座间比较确定。对于大多数患者,HLAMatchmaker可以识别某些错配的HLA抗原,这些抗原与患者的HLA表型为零重联错配,因此应被认为是完全组织相容的。本研究旨在确定三联体水平上的I类HLA匹配如何影响肾脏移植的结局。方法:我们分析了两个多中心数据库,这些数据库从1987年至1999年移植了零HLA-DR不匹配的肾脏。一个数据库由美国移植中心在美国器官共享网络中注册的31,879例同种异体移植物组成,另一个数据库包括15872例在美国移植的肾脏。欧洲移植计划。结果:在三联体水平上相容的HLA-A,B错配肾脏表现出与常规标准定义的零-HLA-A,B抗原错配几乎相同的移植物存活率。三联体匹配的这种有益效果在未致敏和致敏患者以及白人和非白人患者中均可见。结论:这些发现表明,至少在HLA-DR匹配组合中,HLAMatchmaker的应用将增加成功移植的数量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号